Johnson & Johnson (NYSE: JNJ) is considered by many to be a safe stock that works well in portfolios of retirees and risk-averse investors. The pharmaceutical giant pays an above-average dividend yield of 2.6%, and it has increased its payouts annually for 60 consecutive years.

But I'm here today to make the case that Johnson & Johnson (J&J) is being underrated and should be grouped with the growth stock out there. The company has a diverse revenue stream with several divisions posting outsized growth, and it's making moves to maintain that growth over the next few years.

Let's take a closer look at why J&J should get due consideration from growth-oriented investors.

Continue reading

Source Fool.com